Funding of Parkinson research from industry and US federal and foundation sources
Identifieur interne : 002299 ( Main/Exploration ); précédent : 002298; suivant : 002300Funding of Parkinson research from industry and US federal and foundation sources
Auteurs : E. Ray Dorsey [États-Unis] ; Joel P. Thompson [États-Unis] ; Mark Frasier [États-Unis] ; Todd Sherer [États-Unis] ; Brian Fiske [États-Unis] ; Sean Nicholson [États-Unis] ; S. Claiborne Johnston [États-Unis] ; Robert G. Holloway [États-Unis] ; Hamilton Moses Iii [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-04-15.
Descripteurs français
- Pascal (Inist)
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Biomedical Research (economics), Drug Discovery (economics), Drug Discovery (methods), Drug Industry (economics), Financing, Government (economics), Humans, Industry, Nervous system diseases, Parkinson Disease (economics), Parkinson disease, Research Support as Topic (economics), United States, biomedical research, drug development.
- MESH :
- geographic : United States.
- economics : Biomedical Research, Drug Discovery, Drug Industry, Financing, Government, Parkinson Disease, Research Support as Topic.
- methods : Drug Discovery.
- Humans.
Abstract
Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22446
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001637
- to stream Istex, to step Curation: 001637
- to stream Istex, to step Checkpoint: 000F01
- to stream PubMed, to step Corpus: 001E69
- to stream PubMed, to step Curation: 001E69
- to stream PubMed, to step Checkpoint: 001E04
- to stream Ncbi, to step Merge: 002495
- to stream Ncbi, to step Curation: 002495
- to stream Ncbi, to step Checkpoint: 002495
- to stream Main, to step Merge: 002B60
- to stream PascalFrancis, to step Corpus: 000F19
- to stream PascalFrancis, to step Curation: 001E00
- to stream PascalFrancis, to step Checkpoint: 000E71
- to stream Main, to step Merge: 002F68
- to stream Main, to step Curation: 002299
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Funding of Parkinson research from industry and US federal and foundation sources</title><author><name sortKey="Dorsey, E Ray" sort="Dorsey, E Ray" uniqKey="Dorsey E" first="E. Ray" last="Dorsey">E. Ray Dorsey</name></author><author><name sortKey="Thompson, Joel P" sort="Thompson, Joel P" uniqKey="Thompson J" first="Joel P." last="Thompson">Joel P. Thompson</name></author><author><name sortKey="Frasier, Mark" sort="Frasier, Mark" uniqKey="Frasier M" first="Mark" last="Frasier">Mark Frasier</name></author><author><name sortKey="Sherer, Todd" sort="Sherer, Todd" uniqKey="Sherer T" first="Todd" last="Sherer">Todd Sherer</name></author><author><name sortKey="Fiske, Brian" sort="Fiske, Brian" uniqKey="Fiske B" first="Brian" last="Fiske">Brian Fiske</name></author><author><name sortKey="Nicholson, Sean" sort="Nicholson, Sean" uniqKey="Nicholson S" first="Sean" last="Nicholson">Sean Nicholson</name></author><author><name sortKey="Johnston, S Claiborne" sort="Johnston, S Claiborne" uniqKey="Johnston S" first="S. Claiborne" last="Johnston">S. Claiborne Johnston</name></author><author><name sortKey="Holloway, Robert G" sort="Holloway, Robert G" uniqKey="Holloway R" first="Robert G." last="Holloway">Robert G. Holloway</name></author><author><name sortKey="Moses Iii, Hamilton" sort="Moses Iii, Hamilton" uniqKey="Moses Iii H" first="Hamilton" last="Moses Iii">Hamilton Moses Iii</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:98702278CB3FFAF8078BAEDBF281805103A0D553</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22446</idno><idno type="url">https://api.istex.fr/document/98702278CB3FFAF8078BAEDBF281805103A0D553/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001637</idno><idno type="wicri:Area/Istex/Curation">001637</idno><idno type="wicri:Area/Istex/Checkpoint">000F01</idno><idno type="wicri:doubleKey">0885-3185:2009:Dorsey E:funding:of:parkinson</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:19133662</idno><idno type="wicri:Area/PubMed/Corpus">001E69</idno><idno type="wicri:Area/PubMed/Curation">001E69</idno><idno type="wicri:Area/PubMed/Checkpoint">001E04</idno><idno type="wicri:Area/Ncbi/Merge">002495</idno><idno type="wicri:Area/Ncbi/Curation">002495</idno><idno type="wicri:Area/Ncbi/Checkpoint">002495</idno><idno type="wicri:Area/Main/Merge">002B60</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:09-0218143</idno><idno type="wicri:Area/PascalFrancis/Corpus">000F19</idno><idno type="wicri:Area/PascalFrancis/Curation">001E00</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000E71</idno><idno type="wicri:doubleKey">0885-3185:2009:Dorsey E:funding:of:parkinson</idno><idno type="wicri:Area/Main/Merge">002F68</idno><idno type="wicri:Area/Main/Curation">002299</idno><idno type="wicri:Area/Main/Exploration">002299</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Funding of Parkinson research from industry and US federal and foundation sources</title><author><name sortKey="Dorsey, E Ray" sort="Dorsey, E Ray" uniqKey="Dorsey E" first="E. Ray" last="Dorsey">E. Ray Dorsey</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester Medical Center, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Thompson, Joel P" sort="Thompson, Joel P" uniqKey="Thompson J" first="Joel P." last="Thompson">Joel P. Thompson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences, Buffalo, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Frasier, Mark" sort="Frasier, Mark" uniqKey="Frasier M" first="Mark" last="Frasier">Mark Frasier</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Michael J. Fox Foundation for Parkinson's Research, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Sherer, Todd" sort="Sherer, Todd" uniqKey="Sherer T" first="Todd" last="Sherer">Todd Sherer</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Michael J. Fox Foundation for Parkinson's Research, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Fiske, Brian" sort="Fiske, Brian" uniqKey="Fiske B" first="Brian" last="Fiske">Brian Fiske</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Michael J. Fox Foundation for Parkinson's Research, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Nicholson, Sean" sort="Nicholson, Sean" uniqKey="Nicholson S" first="Sean" last="Nicholson">Sean Nicholson</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Policy Analysis and Management, Cornell University, Ithaca, New York</wicri:regionArea><placeName><region type="state">État de New York</region><settlement type="city">Ithaca (New York)</settlement></placeName><orgName type="university">Université Cornell</orgName></affiliation></author><author><name sortKey="Johnston, S Claiborne" sort="Johnston, S Claiborne" uniqKey="Johnston S" first="S. Claiborne" last="Johnston">S. Claiborne Johnston</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of California, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Holloway, Robert G" sort="Holloway, Robert G" uniqKey="Holloway R" first="Robert G." last="Holloway">Robert G. Holloway</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester Medical Center, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Moses Iii, Hamilton" sort="Moses Iii, Hamilton" uniqKey="Moses Iii H" first="Hamilton" last="Moses Iii">Hamilton Moses Iii</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Alerion Institute, North Garden, Virginia</wicri:regionArea><placeName><region type="state">Virginie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-04-15">2009-04-15</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="731">731</biblScope><biblScope unit="page" to="737">737</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">98702278CB3FFAF8078BAEDBF281805103A0D553</idno><idno type="DOI">10.1002/mds.22446</idno><idno type="ArticleID">MDS22446</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biomedical Research (economics)</term><term>Drug Discovery (economics)</term><term>Drug Discovery (methods)</term><term>Drug Industry (economics)</term><term>Financing, Government (economics)</term><term>Humans</term><term>Industry</term><term>Nervous system diseases</term><term>Parkinson Disease (economics)</term><term>Parkinson disease</term><term>Research Support as Topic (economics)</term><term>United States</term><term>biomedical research</term><term>drug development</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Biomedical Research</term><term>Drug Discovery</term><term>Drug Industry</term><term>Financing, Government</term><term>Parkinson Disease</term><term>Research Support as Topic</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Discovery</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Industrie</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies. © 2009 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Virginie</li><li>État de New York</li></region><settlement><li>Ithaca (New York)</li></settlement><orgName><li>Université Cornell</li></orgName></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Dorsey, E Ray" sort="Dorsey, E Ray" uniqKey="Dorsey E" first="E. Ray" last="Dorsey">E. Ray Dorsey</name></region><name sortKey="Fiske, Brian" sort="Fiske, Brian" uniqKey="Fiske B" first="Brian" last="Fiske">Brian Fiske</name><name sortKey="Frasier, Mark" sort="Frasier, Mark" uniqKey="Frasier M" first="Mark" last="Frasier">Mark Frasier</name><name sortKey="Holloway, Robert G" sort="Holloway, Robert G" uniqKey="Holloway R" first="Robert G." last="Holloway">Robert G. Holloway</name><name sortKey="Johnston, S Claiborne" sort="Johnston, S Claiborne" uniqKey="Johnston S" first="S. Claiborne" last="Johnston">S. Claiborne Johnston</name><name sortKey="Moses Iii, Hamilton" sort="Moses Iii, Hamilton" uniqKey="Moses Iii H" first="Hamilton" last="Moses Iii">Hamilton Moses Iii</name><name sortKey="Nicholson, Sean" sort="Nicholson, Sean" uniqKey="Nicholson S" first="Sean" last="Nicholson">Sean Nicholson</name><name sortKey="Sherer, Todd" sort="Sherer, Todd" uniqKey="Sherer T" first="Todd" last="Sherer">Todd Sherer</name><name sortKey="Thompson, Joel P" sort="Thompson, Joel P" uniqKey="Thompson J" first="Joel P." last="Thompson">Joel P. Thompson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002299 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002299 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:98702278CB3FFAF8078BAEDBF281805103A0D553
|texte= Funding of Parkinson research from industry and US federal and foundation sources
}}
| This area was generated with Dilib version V0.6.23. |  |